May 8, 2025, 01:04

Curebound Discovery Grants 2025: $250K for High-Risk, High-Reward Cancer Research

Curebound is now accepting Letters of Intent for the 2025 Discovery Grants, designed to fund early-stage, high-risk, high-reward collaborative cancer research across all cancer types. This grant supports transformative ideas and new areas of inquiry that show promise for follow-on funding and measurable patient impact.

Who is eligible?

Applicants must:

Be independent researchers with an MD, PhD, or equivalent
Hold a faculty appointment at one of six San Diego-based institutions:
- UC San Diego (including Moores Cancer Center and UCSD Health)
- Salk Institute
- Sanford Burnham Prebys
- Rady Children’s Hospital
- La Jolla Institute for Immunology
- Scripps Research
Collaborate with at least one Partner PI from a different eligible institution
Additional co-PIs may be added upon full proposal invitation

Funding at a glance:

Up to 250,000 USD for 1 year (direct + indirect costs)
Indirect costs are capped at 30% of the total budget or 42.85% of direct costs
Funds may cover PI salary (NIH cap), research personnel, supplies, and reagents
Travel, tuition, and non-research infrastructure expenses are not allowed

Research focus:

Projects should explore emerging targets, biomarkers, diagnostics, therapeutic strategies, or screening tools. Priority is given to concepts aligned with Curebound’s strategic research pillars:

Prevention + Diagnostic Tools
Cancer Equities
Novel Therapeutics + Platforms
Immunotherapies + Personalized Vaccines
Pediatric Cancers

Key deadlines:

Letter of Intent Due: May 5, 2025 (5 PM PDT)
Invitation to Apply: June 17, 2025
Full Proposal Due: July 29, 2025 (5 PM PDT)
Award Notification: December 2025
Project Start Date: January 1, 2026

Where to apply:

Apply through ProposalCentral. Applicants must submit an LOI including project summary, team biosketches, and pillar alignment.

Contact:

Program: [email protected]
Tech support: [email protected] | 1-800-875-2562

cancer cancer innovation Cancer research Collaborative Oncology Curebound Diagnostics Discovery Grants emerging targets High-Risk High-Reward immunotherapy OncoDaily Pediatric cancer proposalCENTRAL San Diego biotech translational research

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research